Due to advances in cancer immunotherapy, including positive results from clinical trials testing new agents and combinations, emerging new technologies for measuring aspects of immunity, and novel candidate biomarkers from early phase trials, the SITC Immune Biomarkers Task Force has reconvened to review state of the art technologies, identify current hurdles to further success and to make recommendations to the field.
Topics being addressed by individual working groups include:
In the video below, published by OncLive, watch as current SITC President Dr. Lisa Butterfield discusses the Immune Biomarkers Task Force.
View current and past Task Force members via the links below:
Validation of Biomarkers to Predict Response to Immunotherapy in Cancer (two-part white paper) Journal for ImmunoTherapy of Cancer, November 2016
Novel Technologies and Emerging Biomarkers for Personalized Cancer Immunotherapy Journal for ImmunoTherapy of Cancer, January 2016
Systematic Evaluation of Immune Regulation and Modulation Journal for ImmunoTherapy of Cancer, March 2017
Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy Journal for ImmunoTherapy of Cancer, May 2017
Click here to view a complete list of current and past published Immune Monitoring Technology Primers in the Journal for ImmunoTherapy of Cancer (JITC).
SITC/iSBTc Cancer Immunotherapy Biomarkers Resource Document: Online resources and useful tools – a compass in the land of biomarker discovery Journal of Translational Medicine, September 2011
Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers Clinical Cancer Research, May 2011
Immuno-Oncology Biomarkers 2010 and Beyond: Perspectives from the iSBTc/SITC Biomarker Taskforce Journal of Translational Medicine, December 2010
A Systematic Approach to Biomarker Discovery; Preamble to "the iSBTc-FDA Taskforce on Immunotherapy Biomarkers" Journal of Translational Medicine, December 2008
NCI/CCR and SITC co-sponsored a 2016 Biomarkers meeting to review the state of the art, discuss current hurdles to further success, and consider recommendations to move the field forward.
The main goals were to provide updated information to a wide audience and solicit stakeholder participation in promoting successful immune biomarker research.
A report of this meeting was published in the Journal for ImmunoTherapy of Cancer (JITC) in March 2017. Click here to read Immunotherapy Biomarkers 2016: Overcoming the Barriers. Also, to learn more about the event and its schedule, click here.
The Department of Immunology, Genetics and Pathology (IGP) at Uppsala University in Sweden is involved in an ongoing effort to collect cancer patient data in an initiative entitled U-CAN. By June of this year, the biobank has grown to approximately ...
It is the recent modest single agent activity of programmed death-ligand 1 and programmed death receptor-1 antibodies for those with breast cancer that is generating hope for use of immunotherapy in breast cancer. To ponder in the meantime, in preparation ...
FYI for those in the Tampa, FL area. Emerging Opportunities--Enhancing Awareness of Clinical Trials The 2017 Breast Immune-Oncology Conference is being held Sat., Oct. 7th at Moffitt Cancer Center. There will be a free companion Patient Advocacy Program ...
DC immunotherapy makes use of the patient's own DCs to activate cancer cell elimination.There is an inherent danger, for example, that the effect of CTLA 4 blockade is not restricted to tumor-specific T cells. resulting in immune-related toxicities that ...
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com